ArticleExperimental and therapeutic medicine2018
Salidroside promotes human periodontal ligament cell proliferation and osteocalcin secretion via ERK1/2 and PI3K/Akt signaling pathways.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- Glipizide Alleviates Periodontitis Pathogenicity via Inhibition of Angiogenesis, Osteoclastogenesis and M1/M2 Macrophage Ratio in Periodontal Tissue.Inflammation · 2023Article
- Article
- Article
- Improvement of polydopamine-loaded salidroside on osseointegration of titanium implants.Chinese medicine · 2022Article
- Salidroside promotes the osteogenic and odontogenic differentiation of human dental pulp stem cells through the BMP signaling pathway.Experimental and therapeutic medicine · 2022Article
- Fibrauretine reduces ischemia/reperfusion injury via RISK/eNOS activation.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salidroside modulates cell proliferation and serves as an anti-inflammatory and anti-apoptotic agent with efficacy against various diseases. The objective of the present study was to investigate the efficacy of salidroside in enhancing the proliferation of human periodontal ligament cells (hPDLCs). hPDLCs were isolated and the effects of salidroside on cell viability, soluble osteocalcin levels and activation of proliferation-associated signaling pathways were determined using a CCK-8 assay, ELISA and Western blotting, respectively. The results indicated that salidroside induced proliferation of hPDLCs, increased secretion of soluble osteocalcin and enhanced activation of extracellular signal-regulated kinase (ERK)1/2 and phosphoinositide-3 kinase (PI3K)/Akt signaling pathways. These factors were upregulated by salidroside in a dose-dependent manner. The results of the present study suggested that salidroside mediated hPDLC proliferation via the ERK1/2 and PI3K/Akt signaling pathways, as well as osteocalcin secretion. Salidroside may therefore be used as a novel therapeutic agent in the treatment of the tooth-supporting apparatus, progressive tooth destruction or periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.